273 related articles for article (PubMed ID: 27185370)
1. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.
Gyanchandani R; Lin Y; Lin HM; Cooper K; Normolle DP; Brufsky A; Fastuca M; Crosson W; Oesterreich S; Davidson NE; Bhargava R; Dabbs DJ; Lee AV
Clin Cancer Res; 2016 Nov; 22(21):5362-5369. PubMed ID: 27185370
[TBL] [Abstract][Full Text] [Related]
2. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
3. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
[TBL] [Abstract][Full Text] [Related]
5. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
[TBL] [Abstract][Full Text] [Related]
6. Multi-gene classifiers for prediction of recurrence in breast cancer patients.
Naoi Y; Noguchi S
Breast Cancer; 2016 Jan; 23(1):12-18. PubMed ID: 25700572
[TBL] [Abstract][Full Text] [Related]
7. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
8. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
[TBL] [Abstract][Full Text] [Related]
9. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Li H; Zhu Y; Burnside ES; Drukker K; Hoadley KA; Fan C; Conzen SD; Whitman GJ; Sutton EJ; Net JM; Ganott M; Huang E; Morris EA; Perou CM; Ji Y; Giger ML
Radiology; 2016 Nov; 281(2):382-391. PubMed ID: 27144536
[TBL] [Abstract][Full Text] [Related]
10. Oncotype DX
Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
[TBL] [Abstract][Full Text] [Related]
11. Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas.
Emmadi R; Canestrari E; Arbieva ZH; Mu W; Dai Y; Frasor J; Wiley E
PLoS One; 2015; 10(12):e0145346. PubMed ID: 26717565
[TBL] [Abstract][Full Text] [Related]
12. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Varga Z; Sinn P; Fritzsche F; von Hochstetter A; Noske A; Schraml P; Tausch C; Trojan A; Moch H
PLoS One; 2013; 8(3):e58483. PubMed ID: 23505515
[TBL] [Abstract][Full Text] [Related]
13. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
D'Alfonso TM; van Laar RK; Vahdat LT; Hussain W; Flinchum R; Brown N; John LS; Shin SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):705-15. PubMed ID: 23774991
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
[TBL] [Abstract][Full Text] [Related]
15. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
Schildgen V; Warm M; Brockmann M; Schildgen O
Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
[TBL] [Abstract][Full Text] [Related]
17. Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
Mutonga M; Speedy S; Rademaker A; Liu D; Uthe R; Jain S; Gradishar WJ; Flaum L; Santa-Maria CA
Breast Cancer Res Treat; 2019 Jul; 176(1):95-100. PubMed ID: 30977026
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Low versus High Recurrence Scores in Estrogen Receptor-Positive, Lymph Node-Negative Invasive Breast Cancer on the Basis of Radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence Scores.
Dialani V; Gaur S; Mehta TS; Venkataraman S; Fein-Zachary V; Phillips J; Brook A; Slanetz PJ
Radiology; 2016 Aug; 280(2):370-8. PubMed ID: 26937802
[TBL] [Abstract][Full Text] [Related]
19. Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.
Patel R; Hovstadius M; Kier MW; Moshier EL; Zimmerman BS; Cascetta K; Jaffer S; Sparano JA; Tiersten A
Cancer; 2022 Oct; 128(20):3602-3609. PubMed ID: 35947048
[TBL] [Abstract][Full Text] [Related]
20. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
Allison KH; Kandalaft PL; Sitlani CM; Dintzis SM; Gown AM
Breast Cancer Res Treat; 2012 Jan; 131(2):413-24. PubMed ID: 21369717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
